image
Anixa Biosciences, Inc. ANIX
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 3.23
1.25 %
$ 104 M
Market Cap
-8.5
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ANIX stock under the worst case scenario is HIDDEN Compared to the current market price of 3.23 USD, Anixa Biosciences, Inc. is HIDDEN

ANIX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ANIX stock under the base case scenario is HIDDEN Compared to the current market price of 3.23 USD, Anixa Biosciences, Inc. is HIDDEN

ANIX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ANIX stock under the best case scenario is HIDDEN Compared to the current market price of 3.23 USD, Anixa Biosciences, Inc. is HIDDEN

ANIX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart ANIX

image
1M -5%
6M 25%
1Y 10%
3Y -2%
5Y 6%
All
$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-13.8 M OPERATING INCOME
-25.61%
Growth Rates
1Year -25.61%
3Years -1.73%
5Years -3.81%
7Years -12.47%
10Years -10.61%
-12.7 M NET INCOME
-27.88%
Growth Rates
1Year -27.88%
3Years 1.10%
5Years -1.45%
7Years -14.21%
10Years -2.83%
-7.34 M OPERATING CASH FLOW
-18.13%
Growth Rates
1Year -18.13%
3Years -14.11%
5Years -9.12%
7Years -9.86%
10Years -11.92%
4.28 M INVESTING CASH FLOW
176.33%
Growth Rates
1Year 176.33%
3Years 45.68%
5Years 58.92%
7Years 19.90%
10Years 14.00%
3.42 M FINANCING CASH FLOW
833.06%
Growth Rates
1Year 833.06%
3Years -52.35%
5Years -9.75%
7Years -10.43%
10Years -7.38%
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-3 M OPERATING INCOME
11.31%
Growth Rates
1Year -25.61%
3Years -1.73%
5Years -3.81%
7Years -12.47%
10Years -10.61%
-2.81 M NET INCOME
12.45%
Growth Rates
1Year -27.88%
3Years 1.10%
5Years -1.45%
7Years -14.21%
10Years -2.83%
-1.5 M OPERATING CASH FLOW
48.24%
Growth Rates
1Year -18.13%
3Years -14.11%
5Years -9.12%
7Years -9.86%
10Years -11.92%
2.34 M INVESTING CASH FLOW
-13.36%
Growth Rates
1Year 176.33%
3Years 45.68%
5Years 58.92%
7Years 19.90%
10Years 14.00%
18 K FINANCING CASH FLOW
205.88%
Growth Rates
1Year 833.06%
3Years -52.35%
5Years -9.75%
7Years -10.43%
10Years -7.38%
Balance Sheet Anixa Biosciences, Inc.
image
Current Assets 21.4 M
Cash & Short-Term Investments 19.9 M
Receivables 173 K
Other Current Assets 1.26 M
Non-Current Assets 229 K
Long-Term Investments 0
PP&E 229 K
Other Non-Current Assets 0
92.28 %5.86 %Total Assets$21.6m
Current Liabilities 2.5 M
Accounts Payable 525 K
Short-Term Debt 29 K
Other Current Liabilities 1.95 M
Non-Current Liabilities 203 K
Long-Term Debt 203 K
Other Non-Current Liabilities 0
19.42 %71.99 %7.51 %Total Liabilities$2.7m
EFFICIENCY
Earnings Waterfall Anixa Biosciences, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 13.8 M
Operating Income -13.8 M
Other Expenses -1.13 M
Net Income -12.7 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)000(14m)(14m)1m(13m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
Averages
1Year 0.00%
3Years 41.11%
5Years 29.64%
7Years 30.38%
10Years 37.19%
0.00% OPERATING MARGIN
0.00%
Averages
1Year 0.00%
3Years -1747.97%
5Years -1561.39%
7Years -1954.27%
10Years -1686.91%
0.00% NET MARGIN
0.00%
Averages
1Year 0.00%
3Years -1557.48%
5Years -1439.72%
7Years -1893.50%
10Years -1632.33%
-62.78% ROE
-62.78%
Averages
1Year -62.78%
3Years -49.84%
5Years -60.34%
7Years -112.62%
10Years -138.69%
-58.14% ROA
-58.14%
Averages
1Year -58.14%
3Years -46.98%
5Years -56.77%
7Years -98.78%
10Years -85.22%
-73.17% ROIC
-73.17%
Averages
1Year -73.17%
3Years -55.89%
5Years -64.85%
7Years -121.06%
10Years -103.03%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Anixa Biosciences, Inc.
image
2m2m1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -12.7 M
Depreciation & Amortization 37 K
Capital Expenditures 0
Stock-Based Compensation 4.42 M
Change in Working Capital 526 K
Others 490 K
Free Cash Flow -7.34 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Anixa Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for ANIX of $8.4 , with forecasts ranging from a low of $7 to a high of $10 .
ANIX Lowest Price Target Wall Street Target
7 USD 116.72%
ANIX Average Price Target Wall Street Target
8.4 USD 160.06%
ANIX Highest Price Target Wall Street Target
10 USD 209.60%
Price
Max Price Target
Min Price Target
Average Price Target
10109988776655443322Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Anixa Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
28.5 K USD 1
0-3 MONTHS
70.2 K USD 2
3-6 MONTHS
116 K USD 2
6-9 MONTHS
125 K USD 2
9-12 MONTHS
7. News
ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy? Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 3 weeks ago
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? Here is how ANIXA BIOSCIENCES INC (ANIX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year. zacks.com - 3 weeks ago
Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose SAN JOSE, Calif. , June 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. prnewswire.com - 3 weeks ago
Anixa Biosciences to Host an Investor Webcast on June 26, 2025 SAN JOSE, Calif. , June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT. prnewswire.com - 1 month ago
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now? Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 1 month ago
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage SAN JOSE, Calif. , June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends. prnewswire.com - 1 month ago
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 SAN JOSE, Calif. , June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congress 2025, to be held on June 19-21, 2025 in Vienna, Austria. prnewswire.com - 1 month ago
All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? Here is how ANIXA BIOSCIENCES INC (ANIX) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year. zacks.com - 1 month ago
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview SAN JOSE, Calif. , June 3, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed on NewsNation's "Elizabeth Vargas Reports" to discuss Anixa's breast cancer vaccine. prnewswire.com - 1 month ago
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine SAN JOSE, Calif. , June 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine. prnewswire.com - 1 month ago
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones SAN JOSE, Calif. , May 19, 2025 /PRNewswire/ --  Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today released a letter to shareholders from Chairman and CEO Dr. Amit Kumar, detailing significant progress across its programs and outlining key milestones for the remainder of the year. prnewswire.com - 2 months ago
8. Profile Summary

Anixa Biosciences, Inc. ANIX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 104 M
Dividend Yield 0.00%
Description Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Contact 3150 Almaden Expressway, San Jose, CA, 95118 https://www.anixa.com
IPO Date Oct. 7, 1983
Employees 5
Officers Dr. Amit Kumar Ph.D. Chief Executive Officer, Chairman & Co-Chair of CBAB Mr. Michael J. Catelani CPA, MBA President, Chief Operating Officer, Chief Financial Officer & Corporate Secretary Dr. Pamela D. Garzone Ph.D. Chief Development Officer & Chair Breast Cancer Clinical Advisory Board